Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians

被引:8
|
作者
Macdonald, Courtney [1 ,2 ]
Saunders, Christobel M. [3 ]
Keogh, Louise A. [4 ]
Hunter, Morgan [5 ]
Mazza, Danielle [6 ]
Mclachlan, Sue-Anne [7 ,8 ]
Jones, Sandra C. [9 ]
Nesci, Stephanie [1 ]
Friedlander, Michael L. [10 ,11 ]
Hopper, John L. [12 ]
Emery, Jon D. [13 ,14 ,15 ]
Hickey, Martha [16 ,17 ]
Milne, Roger L. [12 ,18 ,19 ]
Phillips, Kelly-Anne [1 ,2 ,12 ]
机构
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia
[3] Univ Western Australia, Crawley, WA, Australia
[4] Univ Melbourne, Ctr Hlth Equ, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia
[5] Peter MacCallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
[6] Monash Univ, Dept Gen Practice, Melbourne, Vic, Australia
[7] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic, Australia
[8] St Vincents Hosp, Dept Med Oncol, Melbourne, Vic, Australia
[9] Australian Catholic Univ, ACU Engagement, Melbourne, Vic, Australia
[10] Univ New South Wales, Prince Wales Clin Sch, Sydney, NSW, Australia
[11] Prince Wales Hosp, Dept Med Oncol, Randwick, NSW, Australia
[12] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia
[13] Univ Melbourne, Victorian Comprehens Canc Ctr, Dept Gen Practice, Melbourne, Vic, Australia
[14] Univ Melbourne, Victorian Comprehens Canc Ctr, Ctr Canc Res, Melbourne, Vic, Australia
[15] Univ Western Australia, Sch Primary Aboriginal & Rural Hlth Care, Perth, WA, Australia
[16] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia
[17] Royal Womens Hosp, Melbourne, Vic, Australia
[18] Canc Council Victoria, Canc Epidemiol Div, Melbourne, Vic, Australia
[19] Monash Univ, Precis Med, Sch Clin Sci, Monash Hlth, Melbourne, Vic, Australia
[20] Peter MacCallum Canc Ctr, Res Dept, Melbourne, Vic, Australia
基金
英国医学研究理事会; 欧盟地平线“2020”;
关键词
RISK-ASSESSMENT; ATYPICAL HYPERPLASIA; FOLLOW-UP; TAMOXIFEN; PREVENTION; RALOXIFENE; MANAGEMENT;
D O I
10.1158/1940-6207.CAPR-20-0369
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Guidelines endorse the use of chemoprevention for breast cancer risk reduction. This study examined the barriers and facilitators to chemoprevention use for Australian women at increased risk of breast cancer, and their clinicians. Surveys, based on the Theoretical Domains Framework, were mailed to 1,113 women at >= 16% lifetime risk of breast cancer who were enrolled in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer cohort study (kConFab), and their 524 treating clinicians. Seven hundred twenty-five women(65%) and 221 (42%) clinicians responded. Only 10 (1.4%) kConFab women had ever taken chemoprevention. Three hundred seventy-eight (52%) kConFab women, two (3%) breast surgeons, and 51 (35%) family physicians were not aware of chemoprevention. For women, the strongest barriers to chemoprevention were side effects (31%) and inadequate information (23%), which operate in the Theoretical Domains Framework domains of "beliefs about consequences" and "knowledge," respectively. Strongest facilitators related to tamoxifen's long-term efficacy (35%, "knowledge," "beliefs about consequences," and "goals" domains), staying healthy for family (13%, "social role" and "goals" domains), and abnormal breast biopsy (13%, "environmental context" domain). The strongest barrier for family physicians was insufficient knowledge (45%, "knowledge" domain) and for breast surgeons was medication side effects (40%, "beliefs about consequences" domain). The strongest facilitators for both clinician groups related to clear guidelines, strong family history, and better tools to select patients ("environmental context and resources" domain). Clinician knowledge and resources, and beliefs about the side-effect consequences of chemoprevention, are key domains that could be targeted to potentially enhance uptake. Prevention Relevance: Despite its efficacy in reducing breast cancer incidence, chemoprevention is underutilised. This survey study of Australian women and their clinicians used behavioural change theory to identify modifiable barriers to chemoprevention uptake, and to suggest interventions such as policy change, educational resources and public campaigns, that may increase awareness and use.
引用
收藏
页码:131 / 144
页数:14
相关论文
共 50 条
  • [21] Interest in breast cancer chemoprevention among older women
    Jennifer Tjia
    Ellyn Micco
    Katrina Armstrong
    Breast Cancer Research and Treatment, 2008, 108 : 435 - 453
  • [22] Acceptance of Chemoprevention by Women at High Risk for Breast Cancer
    Lane, Karen
    Hyunh, Kelly
    Smith, Edie
    Hsiang, David
    Butler, John
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (02) : S180 - S180
  • [23] Interest in breast cancer chemoprevention among older women
    Tjia, Jennifer
    Micco, Ellyn
    Armstrong, Katrina
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 108 (03) : 435 - 453
  • [24] Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention
    Ziv, Elad
    Tice, Jeffrey A.
    Sprague, Brian
    Vachon, Celine M.
    Cummings, Steven R.
    Kerlikowske, Karla
    PLOS ONE, 2017, 12 (01):
  • [25] Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010
    Erika A. Waters
    Timothy S. McNeel
    Worta McCaskill Stevens
    Andrew N. Freedman
    Breast Cancer Research and Treatment, 2012, 134 : 875 - 880
  • [26] The molecular basis of retinoids' use in breast cancer chemoprevention
    Karamouzis, Michalis V.
    Konstantinopoulos, Panagiotis A.
    Papavassiliou, Athanasios G.
    CELLULAR ONCOLOGY, 2007, 29 (03) : 183 - 184
  • [27] Tamoxifen eligibility, net benefit and use for breast cancer chemoprevention among white women in the US
    Freedman, AN
    Graubard, BI
    Rao, RS
    McCaskill-Stevens, W
    Ballard-Barbash, R
    Gail, MH
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (11) : 1314S - 1314S
  • [28] Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010
    Waters, Erika A.
    McNeel, Timothy S.
    Stevens, Worta McCaskill
    Freedman, Andrew N.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (02) : 875 - 880
  • [29] The experience of women at high risk for breast cancer receiving chemoprevention
    Whisenant, Meagan
    Jones, Jessica Trevino
    Brassil, Kelly
    Williams, Loretta A.
    Ponce, Darcy
    Kamat, Sharvari
    Solis, Emily
    Maliackal, Ann
    Walters, Amie
    Warlick, Hannah
    QUALITY OF LIFE RESEARCH, 2022, 31 : S74 - S75
  • [30] Assessment of preference for breast cancer chemoprevention in Japanese young women
    Nagata, C
    JAPANESE JOURNAL OF CANCER RESEARCH, 1997, 88 (09): : 792 - 796